Scalper1 News
Specialty drugmaker Insys Therapeutics (INSY) beat Wall Street’s Q3 estimates Tuesday, sending the stock up around 6% in early trading on the stock market today. Insys’ revenue in the quarter totaled $58.3 million, double the year-earlier quarter and about $1 million above analysts’ consensus, according to Thomson Reuters. Net income decreased slightly to 31 cents a share, beating consensus by 2 cents. Excluding stock-options expenses, profit rose Scalper1 News
Scalper1 News